<DOC>
	<DOCNO>NCT02100007</DOCNO>
	<brief_summary>The purpose study determine safety tolerability ME-344 give combination Hycamtin® patient solid tumor</brief_summary>
	<brief_title>ME-344 Given Combination With Hycamtin® Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histologic cytologic confirm locally advanced metastatic small cell lung cancer , ovarian cancer , cervical cancer ( Part 1 ) ; small cell lung cancer ovarian cancer ( Part 2 ) Patients ovarian small cell lung cancer must fail initial therapy Patients carcinoma cervix must advance disease amenable curative surgery and/or radiation therapy Patients may receive 4 prior regimen therapy Patients may previously receive irinotecan , topotecan topoisomerase I inhibitor ECOG Performance status 01 ( Appendix B ) A minimum life expectancy 12 week Adequate bone marrow , hepatic renal function evidence : Absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L Platelet count &gt; 100 x 109/L Hemoglobin &gt; 9.0 g/dL Serum bilirubin &lt; 1.5 x ULN AST/ALT ( SGOT/SGPT ) &lt; 2.5 x ULN reference laboratory &lt; 5 x ULN presence liver metastases Serum creatinine &lt; 1.5 x ULN creatinine clearance ≥ 60 mL/min measure institutional standard At least 21 day must elapse prior Day 1 Cycle 1 , since radiotherapy , immunotherapy follow major surgery ; surgical incision completely heal . At least 14 day must elapse prior Day 1 Cycle 1 since `` limited palliative radiotherapy '' , define course therapy encompass &lt; 25 % total bone marrow volume exceed 30 GY . Patients tumor involvement Central Nervous System ( CNS ) . SCLC patient previously treat CNS lesion must stable CNS disease least 4 week Patients uncontrolled infection systemic disease Patients clinically significant cardiac disease well control medication ( e.g. , congestive heart failure , symptomatic coronary artery disease e.g . angina , cardiac arrhythmia ) myocardial infarction within last 12 month Patients toxicity last prior therapy recover least Grade 1 , exception Grade 2 alopecia Patients chemotherapy regimen , biologic , targeted therapy within 2 week prior Cycle 1 Day 1 Patients neuropathy &gt; Grade 1 Patients know hypersensitivity component ME344 topotecan study drug product Patients known human immunodeficiency virus ( HIV ) Hepatitis B C ( active , previously treat ) Patients history solid organ transplantation Patients presence concurrent active malignant disease ( disease study ) within last 12 month exception adequately treat insitu carcinoma , basal squamous cell carcinoma , nonmelanomatous skin cancer . Patients psychiatric disorder social geographic situation would preclude study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>relapse</keyword>
	<keyword>advanced</keyword>
	<keyword>metastatic</keyword>
	<keyword>small cell lung cancer</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>refractory</keyword>
</DOC>